Determinants of Propranolol’s Selective Effect on Loss Aversion by Sokol-Hessner, Peter et al.
 Supplemental Analyses 
 
Simple Means 
Mean parameter estimates (with standard errors) on placebo were consistent 
with those observed elsewhere (Sokol-Hessner, Camerer, & Phelps, 2013; Sokol-
Hessner, Hartley, Hamilton, & Phelps, 2014; Sokol-Hessner et al., 2009): loss 
aversion λ = 1.54 (0.15) (taking the mean of individuals’ log(λ) values can reduce 
the biasing effect of skewness; this measure yielded a recovered group mean λ 
of 1.32), risk attitudes ρ = 0.91 (0.05), and consistency µ = 2.48 (0.55).  
 
Additional Analyses of Change in Loss Aversion 
No other factors we examined (including sex, age, initial heart rate, relative 
change in heart rate or systolic blood pressure, or payment on Day 1) 
significantly interacted with propranolol to reduce loss aversion.  
 
Examining ΔλR (the residual change in log(λ) after removing the effect of Day) 
with respect to gender showed that the effect of propranolol was not significant 
for men (p = 0.24) or women (p = 0.95), and that the genders were not 
significantly different (p = 0.51).  
 
Performing a median split on age also yielded no significant effects on ΔλR. Using 
one-sample t-tests to test ΔλR against zero for young and old age groups: young, 
p = 0.29; old, p = 0.91. Using Wilcoxon signed rank tests: young, p = 0.33; old, p 
= 1. Testing the young and old age groups against one another using two-sample 
t-tests, young vs. old ΔλR, p = 0.37. Using the Wilcoxon rank sum test instead, 
young vs. old ΔλR, p = 0.41. Performing the regression using a median split on 
age instead of on BMI yielded no significance for Medication, Age, or Medication 
x Age.  
 
Baseline heart rate (t = 0 minutes, Day 1) was not correlated with ΔλR (r(45) = -
0.17, p = 0.24), and there was no significant difference between ΔλR for high 
baseline vs. low baseline HR participants (median split on baseline HR; two-
sample t-test, p = 0.14). ΔλR also did not correlate with the effect of propranolol 
relative to placebo on HR (r(45) = -0.01, p = 0.92) or systolic blood pressure 
(r(45) = -0.096, p = 0.52). If we performed our main regression using the change 
in HR on propranolol minus placebo either to do a median split or as a 
continuous variable, we found no significant effects of Medication, ΔHR (or ΔHR 
group), or Medication x ΔHR (or ΔHR group). Similarly, if we regress the change 
in log(λ) on Day and difference in HR change (the difference between the change 
in HR on Day 2 [from t=0 to t=90 minutes] and the change in HR on Day 1), there 
is a strong effect of Day (p = 0.001), but no effect of difference in HR change (p = 
0.53). 
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 If we restrict analysis to those participants who had a larger decrease in systolic 
blood pressure on propranolol compared to placebo (N = 35), and regress 
change in log(λ) on Day and Medication, we find a significant effect of Day (p = 
0.002), but no significant effect of Medication (p = 0.57). Similarly, if we analyze 
only participants with a larger decrease in HR on propranolol compared to 
placebo (N = 40), we recover a significant effect of Day (p = 0.003), but not of 
Medication (p = 0.51). Finally, analyzing only participants with larger decreases in 
HR and systolic blood pressure on propranolol compared to placebo (N = 29) 
yields nearly identical results as above (Day, p = 0.003; Medication, p = 0.73). 
 
Participants’ weight was highly correlated with BMI (r(45) = 0.89, p = 1.5×10-16). It 
was therefore unsurprising that we found similar patterns as those reported in the 
main text if we used weight instead of BMI. Using one-sample t-tests to test ΔλR 
against zero for low and high weight groups (median split): low, p = 0.06; high, p 
= 0.36. Using Wilcoxon signed rank tests: low, p = 0.056; high, p = 0.47. Testing 
the low and high weight groups against one another using two-sample t-tests, low 
vs. high weight ΔλR, p = 0.04. Using the Wilcoxon rank sum test instead, low vs. 
high weight ΔλR, p = 0.05. Performing the regression using a median split on 
weight instead of on BMI yielded a Medication x Weight group interaction, p = 
0.05.  
 
Analyses with BMI as a strictly linear, continuous variable produced similar 
results as with the median split. BMI was marginally correlated with ΔλR (r(45) = -
0.28, p = 0.06), consistent with a larger effect of propranolol in low-BMI 
individuals. If we simply used BMI as a covariate in the regression (assuming a 
strictly linear relationship), the interaction between Medication and BMI was 
trending (p = 0.11), though this model is very implausible for reasons discussed 
in the main manuscript (e.g. the likely presence of floor and/or ceiling effects). 
 
Payment on Day 1 was not significantly correlated with the change in log(λ) 
across days (r(45) = -0.03, p = 0.83). 
 
The nonlinear regression performed in the text (see Equations 1 & 2) estimated 
values of α and γ that effectively created a step function (see Figure S1 for a 
graph of tBMI versus BMI) with 20 participants in the “low BMI” group (9M/11F), 
and 27 in the “high BMI” group (16M/11F). These values should be treated as 
“approximate”. When a step function becomes sufficiently sharp, an infinite 
number of parameter values can describe that sharp step with comparable 
predictive accuracy and quality of fit. Re-doing the estimation three times, for 
example, produced α = 160.2, 150.4, 159.2, and γ = 435.2, 408.9, and 432.6, but 
these values do not describe appreciably different transformations. Unfortunately, 
such discontinuity prevents the estimation of significance values or confidence 
intervals.  
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 Body Mass Index and Other Variables 
BMI correlated with Age (r(45) = 0.34, p = 0.02), but as observed above, Age did 
not account for the change in loss aversion. The low BMI group was significantly 
younger than the high BMI group (24.3 vs. 28.9 years old; p = 0.001).  
 
Gender was not significantly different between the BMI groups (Fisher’s exact 
test, p = 0.39). Nor was BMI significantly different between those who correctly 
guessed which day they received propranolol (p = 0.38). 
 
BMI did not significantly correlate with the effect of propranolol on systolic blood 
pressure (r(45) = 0.17, p = 0.25), though there was a significant correlation with 
propranolol’s effect on the difference in heart rate (r(45) = 0.31, p = 0.03), in 
which low BMI participants had a marginally greater effect of the medication (-9.3 
beats/min, p = 8 ×10-5) compared to high BMI participants (-5.0 beats/min, p = 
0.002; low vs. high BMI groups, p = 0.08). BMI also correlated positively with the 
baseline heart rate on Day 1 (r(45) = 0.43, p = 0.003).  
 
As noted above, none of the above-discussed variables themselves predict 
change in loss aversion across days or do so in interaction with medication. 
 
One possible mediating factor between BMI and propranolol’s effect on loss 
aversion could be insulin. Obesity has been linked to lower insulin receptor 
sensitivity (i.e. insulin resistance; Dallman, 2010; Kullmann et al., 2012), and that 
this may be related to impaired memory or attention (Cholerton, Baker, & Craft, 
2013; Maayan, Hoogendoorn, Sweat, & Convit, 2011; Reger et al., 2008). Future 
studies should consider measuring participants’ insulin sensitivity to ascertain 
whether it could mediate the relationship between propranolol, BMI, and behavior.  
 
Other analyses 
Propranolol did not affect the probability of taking a gamble after a win outcome 
(paired t-test, p = 0.62), loss outcome (p = 0.62), or guaranteed outcome (p = 
0.48).  
 
Physiological Responses to Propranolol 
As expected, propranolol (relative to placebo) strongly reduced heart rate and 
systolic blood pressure from 0-90 minutes (p = 5.1×10-7; p = 8.1×10-7), but had no 
effect on diastolic blood pressure (p = 0.74). Comparing the measurements 
taking at t = 90m and t = 130m, there was no difference in either systolic blood 
pressure or heart rate on either day (all p’s > 0.15). A regression on the change 
in systolic blood pressure from 0-90 minutes indicated no interaction with BMI 
group (p = 0.39), while the same regression on heart rate found a significant 
interaction (p = 0.049), indicating that low-BMI individuals experienced a larger 
effect of propranolol in decreasing their heart rate (-9.25 bmp) than high-BMI 
individuals (-4.96 bmp; two-sample t-test, p = 0.08). However, note that 
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 regressions reported above did not find an effect of heart rate on log loss 
aversion. 
 
Dose Dependence with Propranolol 
It is difficult to determine whether the psychological effects of propranolol in the 
prior literature are in any way dose-dependent, as the vast majority of studies do 
not report any analyses (successful or failed) that leverage relative dose size (i.e. 
taking into account BMI or weight). See Table S1 for a summary of studies 
administering propranolol. 
 
Two of the studies in Table S1 do, however, bring attention to this problem 
(Maheu, Joober, Beaulieu, & Lupien, 2004; van Stegeren, Everaerd, Cahill, 
McGaugh, & Gooren, 1998). Van Stegeren et al (2005) noted that “in animal 
research, the dosage used to test for certain effects is almost always related to 
the body weight of the subject animal. In human studies, on the contrary, this is 
hardly ever done.” This observation was made in the context of an observed 
effect of gender that the authors thought could in reality be dose-dependence: “it 
might simply be so that the relative dosage of 80 mg propranolol for men was 
lower than for women, since their body weight was higher than that of the 
women.”  
 
Loss Aversion over Multiple Days 
In the main text, we report a strong effect of day, in that participants are, on 
average, more loss averse on Day 2 than Day 1. Previous studies using this 
paradigm have not measured loss aversion on multiple days (Sokol-Hessner, et 
al., 2013; Sokol-Hessner, et al., 2014; Sokol-Hessner, et al., 2009), and so we 
are unable to comment on whether this is unique to this study, or a more 
common finding. Speculatively, we believe this increase may be related to 
participants acting more conservatively on the second day after winning money 
(on average) at the end of the first day. In other words, they took the task “more 
seriously” on Day 2 than Day 1 because the reality of the payouts became very 
concrete. Even this hypothesis, however, seems unlikely, because participants 
were no more consistent on Day 2 than Day 1, and Day 1 payment did not 
predict the change in loss aversion across days (see above).  
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Figure S1: The best-fitting estimated transformation function. See Equation 4 in 
the main text. Red circles are individual participants, the blue line is the median 
BMI (used in the median-split). Untransformed BMIs are on the x-axis, and 
transformed values on the Y-axis. As can be seen, the transformation is a sharp 
step function that transitions between high- and low-BMI participants at nearly 
the same value (~25 kg/m2) as the median BMI (25.8 kg/m2). 
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Table S1. A summary of eighteen studies administering propranolol in humans.  
 
1st Auth. & 
Year of Pub. Dose 
N w/ 
drug 
N 
male 
Mean 
Age  
Weight/ 
BMI 
Test for 
dose? Paradigm Rough Findings 
Cahill 1994 40mg 20 ~9? 27.4 - - 
Drug at encoding for later 
memory test of story. 
Propranolol eliminated benefit to memory from 
emotional content.  
Currie 1988 
40, 80, & 
160mg on sep. 
days 12 12 (19-29) - 
Indirectly; 
No effect. Cognitive tests. 
Propranolol reduced the # of photos recalled, and 
reduced anxiety after drug. 
van Stegeren 
1998 40mg 25 ~8 (18-22) - - Story memory paradigm. 
Propranolol eliminated effect of emotion in improving 
recall & recognition for the emotional story only. 
Harmer 2001 80mg 10 5 27.7 - - 
Emotion recognition 
paradigm. Propranolol sped up reaction times to sad faces.  
Reist 2001 40mg 20 20 ~45 - 
Directly; 
No effect. Emotional story memory. 
Propranolol reduced everyone's recall of emotional 
story, not neutral. 
Pitman 2002 
40mg x 4/day x 
10 days 11-18 ~8? 34.3 - - 
Administered to emergency 
department patients. Propranolol reduced PTSD-associated symptoms. 
Strange 2003 40mg 12 6 24.5 - - Word memory task. 
Emotional words impair memory for prev. non-
emotional word. Propranolol eliminates the effect, as 
does amygdala damage.  
Vaiva 2003 
40mg x 3/day x 
7 days 11 7 23.9 - - 
Administered to emergency 
department patients. 
Propranolol reduced the incidence of PTSD after a 
traumatic event.  
Strange 2004 40mg 12 6 24.7 - - Memory task. 
Propranolol eliminates amygdala response at encoding 
and later hippocampal bump at retrieval.  
Rogers 2004 80mg 15 6 20.07 - - Decision task. Propranolol increased gambling in one type of trial.  
Maheu 2004 40mg or 80mg 25 25 (19-36) - 
Indirectly; 
Yes. 
Emotional story; declarative 
memory test. 
40mg didn't affect memory; 80mg impaired short & 
long-term memory for emotional material (but not 
neutral). 
van Stegeren 
2005 80mg 30 15 20.93 ~70kg - Emotional image watching. 
Propranolol reduced amygdala response to emotional 
images. 
van Stegeren 
2006 80mg 15 7 20.93 - - Emotional image watching. 
Propranolol reduced salivary alpha amylase production 
in response to emotional images. 
Brunet 2008 
40mg + 60mg x 
2 9 5 34.8 - - 
PTSD patients recalling 
memories, then reading 
script. 
Propranolol reduced physiological reactions to the 
highly arousing reliving of their PTSD-related story  
De Martino 
2008 40mg 38 19 ~24 - - 
Attentional blink w/ neutral 
and emotional items.  
Propranolol reduces attentional blink effect regardless 
of target valence.  
Zhang 2011 40mg 58-60 58-60 (20-40) - - 
Iowa Gambling task in 
formerly heroin-dependent 
patients. 
Propranolol blocked the negative effects of stress in 
worsening Iowa Gambling Task performance. 
Schwabe 2011 40mg 34 ~17? 24.3 
22.8 (0.3) 
kg/m^2 - 
Stress & choice-after-
devaluation paradigm. 
Stress made participants devaluation-insensitive; 
propranolol abolished the effect.  
Terbeck 2012 40mg 18 9 22.33 - - IAT. Attenuated implicit racial bias. 
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